Source: Clinical Trials Arena

Aclaris: Aclaris Therapeutics receives US FDA approval for Phase Ia/Ib trial of ATI-052

The US FDA has cleared the IND application of Aclaris to commence the placebo-controlled Phase Ia/Ib study of the ATI-052 antibody. The post Aclaris Therapeutics receives US FDA approval for Phase Ia/Ib trial of ATI-052 appeared first on Clinical Trials Arena.

Read full article »
Aclaris's Competitors | Aclaris's News | Aclaris's Financials
Stay up-to-date with the latest news on Aclaris
Annual Revenue
$5.0-25M
Employees
25-100
Neal Walker's photo - Interim-CEO of Aclaris

Interim-CEO

Neal Walker

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Aclaris